Sector News

UK to pursue deals and acquisitions despite Brexit uncertainty

December 3, 2018
Life sciences

The UK pharmaceutical industry is pressing ahead with M&A activity and is “geared to weather any disruption due to Brexit”, suggest results of a recent survey by EY.

EY’s 19th Capital Confidence Barometer (CCB19), a biannual survey of more than 2,600 executives across 45 countries, has found that 67% of UK life sciences executives have a stable or positive outlook on the impact of Brexit on investment and acquisition activity.

However, globally the picture is less positive, with 51% of the surveyed executives believing that Brexit will negatively impact investments and acquisitions outside the UK and EU, as well as their ability to recruit and retain key talent.

According to the report, the global life sciences industry is on track to achieve $200 billion in deals in 2018, but the outlook appears to be more subdued as only 49% believe the sector economy is improving.

Matt Bartell, UK Life Sciences TAS leader for EY, comments: “It’s no surprise that UK execs are more confident on Brexit compared with their global counterparts.

“Clearly those in the life sciences industry have done their homework and are ahead of many others in ensuring they are prepared to weather the Brexit storm and are able to continue focusing efforts on driving growth through M&A.”

He continued: “We’re already seeing firms prepare by moving parts of their supply chain into the European Economic Area as well as stockpiling medicines to deal with any potential immediate disruption.”

This positive outlook contrasts with potential regulatory upheaval with the post-Brexit relocation of the European Medicines Agency. The move from London to Amsterdam, which will occur on January 1 and result in 30% of staff leaving, will force the agency to scale back its activities.

By Anna Smith

Source: Pharma Times

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend